March 4, 2026, marks the 12th World Obesity Day—a timely reminder that obesity and overweight have evolved into a global public health emergency. According to the World Health Organization’s 2022 data, approximately 16% of adults aged 18 years and older worldwide live with obesity. In China, the situation is equally pressing: national surveillance from 2020 revealed that over half of Chinese adults—more than 50%—are either overweight or obese. This epidemic fuels a growing burden of cardiometabolic disease, including dyslipidemia, type 2 diabetes, and hypercholesterolemia, underscoring the urgent need for effective, evidence-based lipid management strategies.
For many individuals with obesity, lifestyle interventions—including dietary modification and increased physical activity—often yield suboptimal reductions in low-density lipoprotein cholesterol (LDL-C), the primary atherogenic lipoprotein. When LDL-C remains persistently elevated despite behavioral changes, pharmacologic therapy becomes essential. Yet patients frequently ask: “Which medications are most appropriate—and safest—for lowering cholesterol in the context of obesity?”
Statins remain the cornerstone of lipid-lowering therapy. As outlined in the Chinese Guidelines for the Management of Dyslipidemia (2023), high-risk patients should aim for LDL-C levels below 1.8 mmol/L, while very-high-risk individuals—including those with established cardiovascular disease or diabetes plus multiple risk factors—require targets under 1.4 mmol/L. Statins such as atorvastatin and rosuvastatin achieve this primarily by inhibiting hepatic cholesterol synthesis via HMG-CoA reductase blockade.
However, obesity introduces unique pharmacologic challenges. Adiposity is strongly associated with nonalcoholic fatty liver disease (NAFLD) and mild-to-moderate hepatic dysfunction, which may alter drug metabolism and increase susceptibility to statin-related adverse effects—including transaminase elevation and myopathy. Moreover, even at moderate-intensity dosing, up to one-third of obese patients fail to reach recommended LDL-C goals. Escalating statin monotherapy further heightens safety concerns without guaranteeing improved efficacy.
In response, contemporary guidelines increasingly endorse combination therapy. The 2023 Chinese Dyslipidemia Guidelines explicitly recommend adding a cholesterol absorption inhibitor to statin treatment for patients requiring intensified LDL-C lowering. Similarly, the 2024 Chinese Expert Consensus on Lipid Management in Patients with Diabetes states that for very-high- and ultra-high-risk individuals, initiating dual therapy—moderate-intensity statin plus a cholesterol absorption inhibitor—should be considered upfront to achieve ≥50% LDL-C reduction, a threshold linked to plaque stabilization and regression in coronary arteries.
A key advancement in this strategy is the integration of seabomeb, China’s first domestically developed second-generation intestinal cholesterol absorption inhibitor. Marketed as Saishimei Seabomeb Tablets, seabomeb acts selectively in the small intestine to inhibit NPC1L1-mediated cholesterol uptake—complementing statins’ hepatic mechanism. This dual-pathway approach—“blocking absorption” in the gut while “suppressing synthesis” in the liver—produces additive LDL-C lowering with favorable tolerability.
Clinical trial data support this synergy: adding seabomeb to background statin therapy yields an additional ~16% reduction in LDL-C beyond statin monotherapy, significantly improving attainment of stringent guideline-recommended targets. Importantly, seabomeb demonstrates robust pharmacokinetic properties suited for populations with comorbidities common in obesity. It undergoes balanced hepatic and renal elimination—with an overall clearance rate of 93%—minimizing systemic accumulation. Dose adjustment is not required in patients with mild-to-moderate hepatic impairment or chronic kidney disease, offering distinct advantages in real-world clinical practice.
Further enhancing adherence, seabomeb exhibits high bioconversion efficiency: 98–99% of the administered dose is metabolized into its active form, with peak plasma concentrations achieved within 0.5–12 hours post-dose. This rapid onset supports early therapeutic feedback—helping patients recognize tangible improvements in lipid profiles and reinforcing long-term treatment engagement.
Yet pharmacotherapy alone is insufficient. Comprehensive management demands integration with sustained lifestyle intervention. Clinicians should counsel patients on reducing intake of saturated and trans fats; increasing soluble fiber; engaging in ≥150 minutes per week of moderate-intensity aerobic activity; and undergoing lipid panel and liver enzyme monitoring every 3–6 months to assess both efficacy and safety.
In summary, lipid management in obesity is not about selecting a single “brand,” but rather tailoring a rational, patient-centered regimen. For those failing to meet LDL-C goals on statin monotherapy—particularly those with concomitant NAFLD, metabolic syndrome, or high cardiovascular risk—the addition of seabomeb represents a guideline-endorsed, mechanistically synergistic, and clinically validated option. Ultimately, optimal outcomes hinge on combining evidence-based pharmacology with persistent behavioral support—ensuring both short-term lipid control and lifelong cardiovascular protection.